Mereo BioPharma Group plc AIM Rule 17 Disclosure Statement (7301K)
December 17 2018 - 10:44AM
UK Regulatory
TIDMMPH
RNS Number : 7301K
Mereo BioPharma Group plc
17 December 2018
Mereo BioPharma Group plc
("Mereo" or the "Company")
AIM Rule 17 Disclosure Statement
London, 17 December 2018 - Mereo BioPharma Group plc (AIM: MPH),
a clinical stage UK based biopharmaceutical company focused on rare
diseases, announces in accordance with AIM Rule 17 that Richard
Jones, Chief Financial Officer of Mereo, has been appointed as a
Non-Executive Director of Alliance Pharma plc with effect from 1
January 2019.
Enquiries:
Mereo BioPharma Group plc +44 (0)333 023 7300
Denise Scots-Knight, Chief Executive
Officer
Richard Jones, Chief Financial Officer
Cantor Fitzgerald Europe (Nominated
Adviser and Broker) +44 (0)20 7894 7000
Phil Davies
Will Goode
Rick Thompson
RBC Capital Markets (Joint Broker) +44 (0)20 7653 4000
Rupert Walford
Jamil Miah
FTI Consulting (Public Relations Adviser) +44 (0)20 3727 1000
Simon Conway
Brett Pollard
Burns McClellan (US Public Relations
Advisor to Mereo Biopharma) +01 (0) 212 213 0006
Lisa Burns
Ami Bavishi
About Mereo
Mereo is a biopharmaceutical company focused on the development
and commercialization of innovative therapeutics that aim to
improve outcomes for patients with rare diseases. Mereo's strategy
is to selectively acquire product candidates that have already
received significant investment from pharmaceutical companies and
that have substantial preclinical, clinical and manufacturing data
packages. In December 2018, Mereo announced the proposed
combination of Mereo and OncoMed Pharmaceuticals, with the
transaction expected to close in the first half of 2019. Each of
Mereo's four product candidates has previously generated positive
clinical data for Mereo's target indication or in a related
indication. Since inception Mereo has commenced large, randomized,
placebo-controlled Phase 2 clinical trials for all four of the
product candidates:
-- BPS-804 for osteogenesis imperfecta (OI). The Company
recently announced completion of enrolment with 112 adult patients
in a Phase 2b dose ranging study with some initial data expected in
the H1 2019 and top-line dose ranging data in late 2019. A
pediatric Phase 3 study design has also been approved by the EMA.
BPS-804 has orphan designation in the US and EU and has been
accepted into the PRIME and Adaptive Pathways in EU;
-- MPH-966 for alpha-1 antitrypsin deficiency (AATD). The
Company recently announced first patient in in a Phase 2 dose
ranging study in the US with data expected in late 2019;
-- BCT-197 for acute exacerbations of COPD (AECOPD). The Company
announced positive top-line Phase 2 data in December 2017; and
-- BGS-649 for hypogonadotropic hypogonadism (HH). The Company
announced positive top-line Phase 2b data in March 2018.
-- As at September 30, 2018 Mereo had (unaudited) total cash
resources of approximately US$44.6 million
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCUBOVRWBAUAAA
(END) Dow Jones Newswires
December 17, 2018 10:44 ET (15:44 GMT)
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From Apr 2024 to May 2024
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From May 2023 to May 2024